Evidence map›Paper›PMID 36176709›Full record

ArticleFrontiers in pain research (Lausanne, Switzerland)2022

Involvement of TLR2-TLR4, NLRP3, and IL-17 in pain induced by a novel Sprague-Dawley rat model of experimental autoimmune encephalomyelitis.

Andrew J Kwilasz, Madison A Clements, Tracey A Larson, Kevin M Harris, Scott T Litwiler, Brodie J Woodall, Laurel S Todd, Anouk E W Schrama, Eric H Mitten, Steven F Maier and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pain research (Lausanne, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. TLR4 induced TRPM2 mediated neuropathic pain.Frontiers in pharmacology · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Andrew J KwilaszDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Madison A ClementsDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Tracey A LarsonDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Kevin M HarrisDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Scott T LitwilerDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Brodie J WoodallDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Laurel S ToddDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Anouk E W SchramaDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Eric H MittenDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Steven F MaierDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
Anne-Marie Van DamDepartment of Anatomy and Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.
Kenner C RiceDrug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States.
Linda R WatkinsDepartment of Psychology and Neuroscience, University of Colorado, Boulder, CO, United States.
University of Colorado Boulder · USAmsterdam University Medical Centers · NLNational Institute on Alcohol Abuse and Alcoholism · US

Funding

Targeting toll like receptor 4 (TLR4) and TLR2 to resolve EAE-associated paralysis, pain and cognitive deficits: efficacy of a clinically-relevant blood brain barrier permeable TLR4/TLR2 antagonistR01NS097313 · NINDS · UNIVERSITY OF COLORADO · PI WATKINS, LINDA · 2016 to 2020
$1.7M
NINDS NIH HHS R01 NS097313
6 · The paper itself

Abstract

Up to 92% of patients suffering from multiple sclerosis (MS) experience pain, most without adequate treatment, and many report pain long before motor symptoms associated with MS diagnosis. In the most commonly studied rodent model of MS, experimental autoimmune encephalomyelitis (EAE), motor impairments/disabilities caused by EAE can interfere with pain testing. In this study, we characterize a novel low-dose myelin-oligodendrocyte-glycoprotein (MOG)-induced Sprague-Dawley (SD) model of EAE-related pain in male rats, optimized to minimize motor impairments/disabilities. Adult male SD rats were treated with increasing doses of intradermal myelin-oligodendrocyte-glycoprotein (MOG

Indexed as

experimental autoimmune encephalomyelitisinterleukin-17NLRP3Sprague-Dawley ratsTLR2–TLR4

Identifiers

PMID36176709
PMCPMC9513159
OpenAlexW4295537975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.